Sun Pharmaceutical Industries, together with its subsidiaries, has signed definitive agreements to acquire multinational generic manufacturer Taro Pharmaceutical Industries (TAROF, Pink Sheets), in an all-cash deal worth $454 million.
According to an official release issued by the company to the BSE today, it intends to fund the acquisition with internal accruals and proceeds from its earlier $350 million FCCB. This deal values Taro's equity at $230 million, or $7.75 per share which is at a 27% premium to its May 18, 2007 closing price of $6.10.
Sun Pharma will also refinance $224 million in net debt of Taro. In addition, to provide immediate liquidity for Taro, the company will provide interim financing to the extent of $45 million, the release said.
Taro has established subsidiaries, manufacturing and products across USA, Israel, Canada. North America represents more than 90% of its sales. It has a strong franchise in dermatology and topical products, in addition to product baskets in cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories, the release added.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment